{"generic":"Pasireotide Diaspartate","drugs":["Pasireotide Diaspartate","Signifor"],"mono":{"0":{"id":"930332-s-0","title":"Generic Names","mono":"Pasireotide Diaspartate"},"1":{"id":"930332-s-1","title":"Dosing and Indications","sub":[{"id":"930332-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Pancreatic fistula, Postoperative; Prophylaxis:<\/b> 900 mcg SUBQ twice daily for 7 days, initiated preoperatively on morning of procedure<\/li><li><b>Pituitary dependent hypercortisolism, No surgical option or not curative:<\/b> initial 0.6 mg or 0.9 mg SUBQ twice daily; range, 0.3 mg to 0.9 mg SUBQ twice daily; titrate based on response and tolerability<\/li><\/ul>"},{"id":"930332-s-1-5","title":"Pediatric Dosing","mono":"efficacy and safety not established in pediatric patients "},{"id":"930332-s-1-6","title":"Dose Adjustments","mono":"<ul><li><b>geriatric:<\/b> start at low end of dosing range<\/li><li><b>hepatic impairment, mild (Child-Pugh A):<\/b> no dosage adjustment necessary<\/li><li><b>hepatic impairment, moderate (Child-Pugh B):<\/b> initial dose, 0.3 mg subQ twice daily; MAX 0.6 mg twice a day<\/li><li><b>hepatic impairment, severe (Child-Pugh C):<\/b> avoid use<\/li><li><b>renal:<\/b> no dosage adjustment necessary<\/li><li><b>adverse events:<\/b> reduce dose by decrements of 0.3 mg per injection<\/li><\/ul>"},{"id":"930332-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Pituitary dependent hypercortisolism, No surgical option or not curative<br\/><b>Non-FDA Labeled Indications<\/b><br\/>Pancreatic fistula, Postoperative; Prophylaxis<br\/>"}]},"3":{"id":"930332-s-3","title":"Contraindications\/Warnings","sub":[{"id":"930332-s-3-9","title":"Contraindications","mono":"specific contraindications have not been determined <br\/>"},{"id":"930332-s-3-10","title":"Precautions","mono":"<ul><li>bradycardia has been reported; increased risk with cardiac disease, high-grade heart block, history of significant bradycardia, and concomitant use of drugs associated with bradycardia; monitoring recommended<\/li><li>cholelithiasis has been reported; monitoring recommended<\/li><li>elderly patients; consider lower initial doses<\/li><li>hepatic impairment; dose adjustment may be necessary<\/li><li>hyperglycemia, some cases severe, including development of prediabetes, diabetes, or associated complications (eg, ketoacidosis) has been reported; increased risk with poor glycemic control at baseline; monitoring recommended; dose reduction or discontinuation of therapy may be necessary<\/li><li>hypocortisolism may occur; monitoring recommended; temporary dose reduction or interruption of treatment, and short-term low-dose glucocorticoid replacement therapy may be necessary<\/li><li>liver enzyme elevations have been reported; monitoring recommended<\/li><li>pituitary hormone (other than adrenocorticotropic hormone (ACTH)) inhibition may occur; increased risk with prior transsphenoidal surgery and pituitary irradiation; monitoring recommended<\/li><li>QT prolongation has been reported; increased risk with congenital long QT prolongation, uncontrolled or significant cardiac disease (recent myocardial infarction, congestive heart failure, unstable angina, clinically significant bradycardia), hypokalemia, hypomagnesemia, concomitant antiarrhythmic therapy, or use of other QT-prolonging agents; monitoring recommended<\/li><li>report suspected adverse reactions to the US Food and Drug Administration at 1-800-FDA-1088 or www.fda.gov\/medwatch<\/li><\/ul>"},{"id":"930332-s-3-11","title":"Pregnancy Category","mono":"<ul><li>Pasireotide: C (FDA)<\/li><li>Pasireotide: B3 (AUS)<\/li><\/ul>"},{"id":"930332-s-3-12","title":"Breast Feeding","mono":"Pasireotide: Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"930332-s-4","title":"Drug Interactions","sub":[{"id":"930332-s-4-13","title":"Contraindicated","mono":"<ul><li>Amifampridine (theoretical)<\/li><li>Bepridil (theoretical)<\/li><li>Cisapride (theoretical)<\/li><li>Dronedarone (theoretical)<\/li><li>Mesoridazine (established)<\/li><li>Pimozide (theoretical)<\/li><li>Piperaquine (theoretical)<\/li><li>Saquinavir (theoretical)<\/li><li>Sparfloxacin (theoretical)<\/li><li>Terfenadine (theoretical)<\/li><li>Thioridazine (theoretical)<\/li><li>Ziprasidone (theoretical)<\/li><\/ul>"},{"id":"930332-s-4-14","title":"Major","mono":"<ul><li>Acarbose (theoretical)<\/li><li>Albiglutide (theoretical)<\/li><li>Alfuzosin (theoretical)<\/li><li>Alogliptin (theoretical)<\/li><li>Amiodarone (theoretical)<\/li><li>Amitriptyline (theoretical)<\/li><li>Anagrelide (theoretical)<\/li><li>Apomorphine (theoretical)<\/li><li>Aripiprazole (theoretical)<\/li><li>Arsenic Trioxide (theoretical)<\/li><li>Asenapine (theoretical)<\/li><li>Astemizole (theoretical)<\/li><li>Atazanavir (theoretical)<\/li><li>Azithromycin (theoretical)<\/li><li>Bedaquiline (theoretical)<\/li><li>Buserelin (theoretical)<\/li><li>Canagliflozin (theoretical)<\/li><li>Chloroquine (theoretical)<\/li><li>Chlorpromazine (theoretical)<\/li><li>Chlorpropamide (theoretical)<\/li><li>Ciprofloxacin (theoretical)<\/li><li>Citalopram (theoretical)<\/li><li>Clarithromycin (theoretical)<\/li><li>Clomipramine (theoretical)<\/li><li>Clozapine (theoretical)<\/li><li>Crizotinib (theoretical)<\/li><li>Cyclobenzaprine (theoretical)<\/li><li>Dabrafenib (theoretical)<\/li><li>Dapagliflozin (theoretical)<\/li><li>Dasatinib (theoretical)<\/li><li>Degarelix (theoretical)<\/li><li>Delamanid (theoretical)<\/li><li>Desipramine (theoretical)<\/li><li>Deslorelin (theoretical)<\/li><li>Disopyramide (theoretical)<\/li><li>Dofetilide (theoretical)<\/li><li>Dolasetron (theoretical)<\/li><li>Domperidone (theoretical)<\/li><li>Donepezil (probable)<\/li><li>Doxepin (theoretical)<\/li><li>Droperidol (theoretical)<\/li><li>Dulaglutide (theoretical)<\/li><li>Ebastine (theoretical)<\/li><li>Empagliflozin (theoretical)<\/li><li>Eribulin (theoretical)<\/li><li>Erythromycin (theoretical)<\/li><li>Escitalopram (theoretical)<\/li><li>Exenatide (theoretical)<\/li><li>Famotidine (theoretical)<\/li><li>Felbamate (theoretical)<\/li><li>Fingolimod (theoretical)<\/li><li>Flecainide (theoretical)<\/li><li>Fluconazole (theoretical)<\/li><li>Fluoxetine (theoretical)<\/li><li>Formoterol (theoretical)<\/li><li>Foscarnet (theoretical)<\/li><li>Fosphenytoin (theoretical)<\/li><li>Galantamine (theoretical)<\/li><li>Gatifloxacin (theoretical)<\/li><li>Gemifloxacin (theoretical)<\/li><li>Glimepiride (theoretical)<\/li><li>Glipizide (theoretical)<\/li><li>Glyburide (theoretical)<\/li><li>Gonadorelin (theoretical)<\/li><li>Goserelin (theoretical)<\/li><li>Granisetron (theoretical)<\/li><li>Halofantrine (theoretical)<\/li><li>Haloperidol (theoretical)<\/li><li>Histrelin (theoretical)<\/li><li>Hydroquinidine (theoretical)<\/li><li>Hydroxychloroquine (probable)<\/li><li>Ibutilide (theoretical)<\/li><li>Iloperidone (theoretical)<\/li><li>Imipramine (theoretical)<\/li><li>Insulin (theoretical)<\/li><li>Insulin Aspart, Recombinant (theoretical)<\/li><li>Insulin Bovine (theoretical)<\/li><li>Insulin Degludec (theoretical)<\/li><li>Insulin Detemir (theoretical)<\/li><li>Insulin Glulisine (theoretical)<\/li><li>Insulin Lispro, Recombinant (theoretical)<\/li><li>Itraconazole (theoretical)<\/li><li>Ivabradine (theoretical)<\/li><li>Ketoconazole (theoretical)<\/li><li>Lapatinib (theoretical)<\/li><li>Leuprolide (theoretical)<\/li><li>Levofloxacin (theoretical)<\/li><li>Linagliptin (theoretical)<\/li><li>Liraglutide (theoretical)<\/li><li>Lixisenatide (theoretical)<\/li><li>Lumefantrine (theoretical)<\/li><li>Mefloquine (theoretical)<\/li><li>Metformin (theoretical)<\/li><li>Methadone (theoretical)<\/li><li>Metronidazole (theoretical)<\/li><li>Mifepristone (theoretical)<\/li><li>Miglitol (theoretical)<\/li><li>Mizolastine (theoretical)<\/li><li>Moxifloxacin (theoretical)<\/li><li>Nafarelin (theoretical)<\/li><li>Nateglinide (theoretical)<\/li><li>Nelfinavir (theoretical)<\/li><li>Nilotinib (theoretical)<\/li><li>Norfloxacin (theoretical)<\/li><li>Octreotide (theoretical)<\/li><li>Ofloxacin (theoretical)<\/li><li>Olanzapine (theoretical)<\/li><li>Ondansetron (theoretical)<\/li><li>Paliperidone (theoretical)<\/li><li>Panobinostat (theoretical)<\/li><li>Paroxetine (theoretical)<\/li><li>Pazopanib (theoretical)<\/li><li>Pentamidine (theoretical)<\/li><li>Perflutren Lipid Microsphere (theoretical)<\/li><li>Perflutren Protein Type A Microsphere (theoretical)<\/li><li>Perphenazine (theoretical)<\/li><li>Pioglitazone (theoretical)<\/li><li>Pipamperone (theoretical)<\/li><li>Posaconazole (theoretical)<\/li><li>Pramlintide (theoretical)<\/li><li>Probucol (theoretical)<\/li><li>Procainamide (theoretical)<\/li><li>Prochlorperazine (theoretical)<\/li><li>Promethazine (theoretical)<\/li><li>Propafenone (theoretical)<\/li><li>Protriptyline (theoretical)<\/li><li>Quetiapine (theoretical)<\/li><li>Quinidine (theoretical)<\/li><li>Quinine (theoretical)<\/li><li>Ranolazine (theoretical)<\/li><li>Repaglinide (theoretical)<\/li><li>Rilpivirine (theoretical)<\/li><li>Risperidone (theoretical)<\/li><li>Ritonavir (theoretical)<\/li><li>Rosiglitazone (theoretical)<\/li><li>Saxagliptin (theoretical)<\/li><li>Sertindole (theoretical)<\/li><li>Sevoflurane (theoretical)<\/li><li>Sitagliptin (theoretical)<\/li><li>Sodium Phosphate (theoretical)<\/li><li>Sodium Phosphate, Dibasic (theoretical)<\/li><li>Sodium Phosphate, Monobasic (theoretical)<\/li><li>Solifenacin (theoretical)<\/li><li>Sorafenib (theoretical)<\/li><li>Sotalol (theoretical)<\/li><li>Sunitinib (theoretical)<\/li><li>Tacrolimus (theoretical)<\/li><li>Tamoxifen (theoretical)<\/li><li>Telaprevir (theoretical)<\/li><li>Telavancin (theoretical)<\/li><li>Telithromycin (theoretical)<\/li><li>Tetrabenazine (theoretical)<\/li><li>Tizanidine (theoretical)<\/li><li>Tolazamide (theoretical)<\/li><li>Tolbutamide (theoretical)<\/li><li>Tolterodine (theoretical)<\/li><li>Toremifene (theoretical)<\/li><li>Trazodone (theoretical)<\/li><li>Trimipramine (theoretical)<\/li><li>Triptorelin (theoretical)<\/li><li>Vandetanib (theoretical)<\/li><li>Vardenafil (theoretical)<\/li><li>Vemurafenib (theoretical)<\/li><li>Venlafaxine (theoretical)<\/li><li>Vilanterol (theoretical)<\/li><li>Vildagliptin (theoretical)<\/li><li>Vinflunine (theoretical)<\/li><li>Voriconazole (theoretical)<\/li><li>Vorinostat (theoretical)<\/li><\/ul>"}]},"5":{"id":"930332-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Endocrine metabolic:<\/b>Hyperglycemia (38% to 43%)<\/li><li><b>Gastrointestinal:<\/b>Abdominal pain (23% to 25%), Cholelithiasis (30%), Diarrhea (58% to 59%), Nausea (46% to 58%)<\/li><li><b>Neurologic:<\/b>Headache (28% to 29%)<\/li><li><b>Other:<\/b>Fatigue (15% to 24%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Prolonged QT interval (6%), Sinus bradycardia (3% to 10%)<\/li><li><b>Endocrine metabolic:<\/b>Diabetes mellitus (16% to 20%), Secondary hypocortisolism<\/li><\/ul>"},"6":{"id":"930332-s-6","title":"Drug Name Info","sub":{"0":{"id":"930332-s-6-17","title":"US Trade Names","mono":"Signifor<br\/>"},"2":{"id":"930332-s-6-19","title":"Class","mono":"Somatostatin (class)<br\/>"},"3":{"id":"930332-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"930332-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"930332-s-7","title":"Mechanism Of Action","mono":"Pasireotide diaspartate is a cyclohexapeptide somatostatin analogue that exerts its activity by binding to somatostatin receptors. Adrenocorticotropic hormone (ACTH) secretion is inhibited leading to decreased cortisol secretion.<br\/>"},"8":{"id":"930332-s-8","title":"Pharmacokinetics","sub":[{"id":"930332-s-8-23","title":"Absorption","mono":"<ul><li>Tmax, subQ, healthy volunteers: 0.25 to 0.5 hour<\/li><li>Tmax, subQ, hepatic impairment, moderate to severe: 0.67 to 1 hour<\/li><\/ul>"},{"id":"930332-s-8-24","title":"Distribution","mono":"<ul><li>Protein binding: 88%<\/li><li>Vd: greater than 100 L<\/li><li>Vd, hepatic impairment, severe or moderate: 200 or 226 L<\/li><\/ul>"},{"id":"930332-s-8-25","title":"Metabolism","mono":"<ul><li>Hepatic: predominant<\/li><li>Renal: minor<\/li><li>CYP450 levels may decrease due to suppression of growth hormone secretion<\/li><\/ul>"},{"id":"930332-s-8-26","title":"Excretion","mono":"<ul><li>Fecal: 48.3%, mostly unchanged<\/li><li>Renal: 7.63%, mostly unchanged<\/li><li>Total body clearance, Cushing disease: 3.8 L\/hr<\/li><li>Total body clearance, healthy volunteers: 7.82 to 13.1 L\/hr<\/li><li>Total body clearance, hepatic impairment, moderate or severe: 4.3 to 4.8 L\/hr<\/li><\/ul>"},{"id":"930332-s-8-27","title":"Elimination Half Life","mono":"<ul><li>healthy volunteers, 9 to 12 hours<\/li><li>hepatic impairment, 22.1 to 36.4 hours<\/li><\/ul>"}]},"9":{"id":"930332-s-9","title":"Administration","mono":"<b>Subcutaneous<\/b><br\/><ul><li>insert the needle into pinched skin of thigh or abdomen subcutaneously at a 45 degree angle and press plunger down until the syringe is empty<\/li><li>rotate injection site with each dose; do not inject into skin that is red or irritated<\/li><li>use of the same site for 2 consecutive injections is not recommended, and avoid multiple subQ injections at the same site within short periods of time<\/li><\/ul>"},"10":{"id":"930332-s-10","title":"Monitoring","mono":"<ul><li>clinically meaningful reduction in 24-hour urinary free cortisol indicates efficacy<\/li><li>improvements in signs and symptoms of disease indicates efficacy<\/li><li>fasting plasma glucose or hemoglobin A1c; at baseline<\/li><li>fasting plasma glucose or patient self-monitoring of blood glucose; every week for the first 2 to 3 months and periodically thereafter<\/li><li>potassium and magnesium levels; at baseline and periodically during therapy.<\/li><li>liver tests; at baseline and after 1 to 2 weeks after treatment initiation, then monthly for 3 months, and every 6 months thereafter.<\/li><li>pituitary function (eg, TSH, free T(4), growth hormone (GH), insulin-like growth factor (IGF-1)); at baseline and periodically during therapy, especially in patients who have undergone transsphenoidal surgery or pituitary irradiation<\/li><li>signs and symptoms associated with hypocortisolism (eg, weakness, fatigue, anorexia, nausea, vomiting, hypotension, hyponatremia, and hypoglycemia)<\/li><li>ECG; at baseline<\/li><li>effect on QT interval<\/li><li>bradycardia; in patients with cardiac disease or risk factors for bradycardia (eg, high-grade heart block, history of clinically significant bradycardia, or concomitant use of drugs that may cause bradycardia)<\/li><li>gallbladder ultrasound; prior to therapy and every 6 to 12 months during therapy<\/li><\/ul>"},"11":{"id":"930332-s-11","title":"How Supplied","mono":"<b>Signifor<\/b><br\/>Subcutaneous Solution: 0.3 MG\/ML, 0.6 MG\/ML, 0.9 MG\/ML<br\/>"},"12":{"id":"930332-s-12","title":"Toxicology","sub":[{"id":"930332-s-12-31","title":"Clinical Effects","mono":"<b>OCTREOTIDE AND RELATED AGENTS<\/b><br\/>OVERDOSE: Overdose data are limited with these agents; hypoglycemia, flushing, dizziness and nausea have been reported. ADVERSE EFFECTS: Gastrointestinal adverse effects (eg; anorexia, nausea, vomiting, diarrhea and steatorrhea, constipation, abdominal discomfort, and flatulence) are the most common effects.  Gallstones, hypoglycemia and hyperglycemia, dizziness, pancreatitis, hypothyroidism, sinus bradycardia, conduction abnormalities, dysrhythmias, thrombocytopenia, and hepatitis have also been reported.<br\/>"},{"id":"930332-s-12-32","title":"Treatment","mono":"<b>OCTREOTIDE AND RELATED AGENTS <\/b><br\/><ul><li>Decontamination: Significant toxicity is not anticipated after ingestion because of limited  bioavailability.  Treatment is symptomatic and supportive.  Consider activated charcoal only after very large ingestions.<\/li><li>Hyperglycemia: If significant hyperglycemia occurs, careful blood glucose monitoring and insulin therapy might be required.<\/li><li>Hypoglycemia: Give dextrose if symptomatic or BS &lt;60 mg\/dL. Dose - Adult 50 mL of 50% dextrose IV push; Child 0.5 to 1 g\/kg (2-4 mL\/kg) of 25% dextrose IV push. Feed oral carbohydrates. If recurrent hypoglycemia develops, repeat dextrose bolus and follow with an infusion of 10% dextrose; titrate to a BS of 100 mg\/dL.<\/li><li>Bradycardia: ATROPINE: ADULT DOSE: BRADYCARDIA: 0.5 to 1 mg IV every 5 min. ASYSTOLE: 1 mg IV every 5 min.  Maximum total dose 3 mg or 0.04 mg\/kg.  Minimum single dose 0.5 mg. PEDIATRIC DOSE: 0.02 mg\/kg IV repeat every 5 min, minimum single dose 0.1 mg; maximum single dose child 0.5 mg, adolescent 1 mg; maximum total dose 1 mg child, 2 mg adolescent.<\/li><li>Monitoring of patient: Vital signs, liver enzyme levels, blood glucose level, electrolytes and fluid status, ECG, and continuous cardiac monitoring in symptomatic patients.<\/li><\/ul>"},{"id":"930332-s-12-33","title":"Range of Toxicity","mono":"<b>OCTREOTIDE AND RELATED AGENTS<\/b><br\/>A minimum toxic dose has not been established has not been established for these agents. Overdoses of octreotide up to 120,000 mcg infused over 8 hours have been well tolerated.  Octreotide doses of 2.5 mg (2500 mcg) subcutaneously have caused hypoglycemia, flushing, dizziness, and nausea.<br\/>"}]},"13":{"id":"930332-s-13","title":"Clinical Teaching","mono":"<ul><li>Advise patient to report signs or symptoms of hypocortisolism, such as weakness, fatigue, anorexia, nausea, vomiting, hypotension and symptoms of hyponatremia or hypoglycemia.<\/li><li>Instruct patient to report signs or symptoms of hyperglycemia, such as excessive thirst, high urine output, increased appetite with weight loss, or fatigue.<\/li><li>Counsel patient to report abnormal heart rhythm or signs or symptoms of bradycardia (eg, dizziness, weakness, fainting).<\/li><li>Drug may cause diarrhea, nausea, cholelithiasis, headache, abdominal pain, and fatigue.<\/li><li>Teach patient to gently pinch skin at injection site and hold needle\/syringe at a 45 degree angle for injection.<\/li><li>Instruct patient avoid multiple injections at or near the same site within short periods of time and to rotate injection sites with each dose.<\/li><li>Recommend patient use top of thigh or abdomen for injection.<\/li><li>Advise patient not to inject into skin that is red or irritated.<\/li><li>Advise patient that there are multiple significant drug-drug interactions for this drug. Consult healthcare professional prior to new drug use (including over-the-counter and herbal drugs).<\/li><\/ul>"}}}